BiotechTube

UX007 + Placebo

Phase 3Terminated
0 watching 0 views this week📈 Rising
72
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)

Conditions

Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)

Trial Timeline

Apr 19, 2017 → Oct 9, 2019

NCT ID
NCT02960217

About UX007 + Placebo

UX007 + Placebo is a phase 3 stage product being developed by Ultragenyx Pharmaceutical for Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS). The current trial status is terminated. This product is registered under clinical trial identifier NCT02960217. Target conditions include Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS).

Hype Score Breakdown

Clinical
27
Activity
18
Company
5
Novelty
9
Community
10

Clinical Trials (2)

NCT IDPhaseStatus
NCT02960217Phase 3Terminated
NCT01993186Phase 2Completed

Competing Products

17 competing products in Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)

See all competitors
ProductCompanyStageHype Score
Aspirin + Alpha lipoic acid + Olmesartan + PlaceboDaiichi SankyoPre-clinical
23
Exenatide + MetforminEli LillyApproved
85
AZD1656AstraZenecaPhase 1
33
Candesartan + PlaceboAstraZenecaApproved
85
Placebo for Sitagliptin 25 mg + Placebo for Sitagliptin 50 mg + Sitagliptin 25 mg + Sitagliptin 50 mgMerckPhase 2
52
Sitagliptin-Metformin + Metformin + Placebo pillMerckApproved
85
Comparator: exenatide + Comparator: exenatide + Comparator: PlaceboMerckPhase 1
33
Placebo + JanuviaMerckPhase 2
52
cyclosporine micro-emulsionNovartisApproved
85
Ramipril + RosiglitazonePfizerPhase 3
76
HSK7653 10mg Q2W + HSK7653 25mg Q2W + PlaceboHaisco Pharmaceutical GroupPhase 2
49
TriheptanoinUltragenyx PharmaceuticalPre-clinical
18
UX007Ultragenyx PharmaceuticalPhase 2
47
TriheptanoinUltragenyx PharmaceuticalPhase 2
47
TriheptanoinUltragenyx PharmaceuticalPhase 2
47
UX007 + PlaceboUltragenyx PharmaceuticalPhase 2
47
GFT505 80mg + PlaceboGenfitPhase 2
44

Other Products from Ultragenyx Pharmaceutical

Crysvita (burosumab-twza) TreatmentApproved
80
GTX-102Phase 3
72
EvinacumabPhase 3
72
Adjuvant Immunomodulatory (IM) TherapyPhase 3
72
Oral prednisolone + Placebo for oral prednisolonePhase 3
72